Biomarker Testing For Patients With Advanced Colorectal Cancer

Andrew Spiegel, Esquire, Co-Founder and Executive Director of the Global Colon Cancer Alliance discusses the expanded “Clear Your View” campaign, a collaboration between Guardant Health and five leading patient advocacy groups that aims to raise awareness about the need for complete biomarker testing for patients with advanced colorectal cancer (CRC).  The campaign encourages physicians to “stop, test and wait” for the complete genomic profile of a patient’s cancer before starting first-line therapy. The growing number of targetable CRC biomarkers makes it imperative that all patients receive complete biomarker testing before starting treatment. 

Andrew Spiegel has a long and personal history of non-profit service. He is co-founder of the Global Colon Cancer Alliance, the leading US based national patient advocacy organization dedicated to colon cancer. Spiegel, an attorney, also served as a longtime board member of the Alliance before becoming CEO in January of 2009. and he ran the CCA for 4 years, before undertaking his next venture, the Global Colon Cancer Association (GCCA). Currently, Spiegel is co-founder and executive director of the GCCA, an international patient advocacy organization. Spiegel is on the Stand Up to Cancer Advocate Advisory Council. He is a co-founder and serves on the steering committee of the Alliance for Safe Biologic Medicines, is current Chair of the Digestive Disease National Coalition (DDNC) and is an active member of many other health care coalitions and organizations.